Yoon-Jae Cho, M.D., Ph.D.
Affiliations: | Pediatric Neurology | Oregon Health and Science University, Portland, OR |
Area:
Neuro-oncologyGoogle:
"Yoon-Jae Cho"Mean distance: 15.51 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Scott L. Pomeroy | post-doc | 2007-2010 | Harvard Medical School/Children's Hospital |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Garancher A, Suzuki H, Haricharan S, et al. (2020) Abstract IA11: Overcoming immune evasion in pediatric brain tumors Cancer Research. 80 |
| Garancher A, Suzuki H, Haricharan S, et al. (2019) IMMU-03. TUMOR NECROSIS FACTOR OVERCOMES IMMUNE EVASION IN P53-MUTANT MEDULLOBLASTOMA Neuro-Oncology. 21: ii93-ii93 |
| Bakhshinyan D, Venugopal C, Adile AA, et al. (2018) BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene |
| Kahn SA, Wang X, Nitta RT, et al. (2018) Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4121 |
| Purzner T, Purzner J, Buckstaff T, et al. (2018) Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma. Science Signaling. 11 |
| Nitta R, Bolin SM, Nwagbo G, et al. (2018) Abstract LB-322: Casein kinase 2 is a major regulator of medulloblastoma growth Cancer Research. 78 |
| Henderson JJ, Wagner JP, Hofmann NE, et al. (2017) Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line. Pediatric Blood & Cancer |
| Gholamin S, Mitra SS, Feroze AH, et al. (2017) Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine. 9 |
| Henderson J, Cho H, Davare M, et al. (2017) PDTM-36. FUNCTIONAL GENOMIC ANALYSIS OF MYC-AMPLIFIED MEDULLOBLASTOMA NOMINATES THE TGFB PATHWAY AS A CLINICALLY VIABLE TARGET Neuro-Oncology. 19: vi197-vi197 |
| Phoenix TN, Patmore DM, Boop S, et al. (2016) Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell |